Speak directly to the analyst to clarify any post sales queries you may have.
The oncolytic virus therapies market is gaining momentum as an innovative area within oncology, promising new treatment options by combining targeted tumor destruction and immune system activation.
Market Snapshot: Oncolytic Virus Therapies Market Overview
The Oncolytic Virus Therapies Market grew from USD 132.50 million in 2024 to USD 153.79 million in 2025. It is expected to continue growing at a CAGR of 16.34%, reaching USD 444.83 million by 2032. This growth is underpinned by increasing research collaboration, technological advances in viral engineering, expanding clinical trial pipelines, and evolving regulatory landscapes. The market’s expansion reflects a strong drive to meet demand for more precise and effective cancer treatments, especially where traditional therapies present limitations. Senior decision-makers seeking insights into therapeutic innovation, strategic investment opportunities, and future adoption trends will find this market becoming a focal point in the cancer care ecosystem.
Scope & Segmentation
This report examines the entire value chain in oncolytic virus therapies, covering therapeutic development, deployment, and commercialization across crucial segmentation points:
- Cancer Indication: Glioblastoma, head and neck cancer, melanoma
- Virus Type: Genetically modified virus (adenovirus, herpes simplex virus, vaccinia virus), wild type virus
- Administration Route: Intratumoral, intravenous
- End User: Hospitals, research institutes, specialty clinics
- Geographic Coverage: Americas (United States, Canada, Mexico, Brazil, Argentina, Chile, Colombia, Peru), Europe, Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, Netherlands, Sweden, Poland, Switzerland, United Arab Emirates, Saudi Arabia, Qatar, Turkey, Israel, South Africa, Nigeria, Egypt, Kenya), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Malaysia, Singapore, Taiwan)
- Key Companies: Amgen Inc., Merck & Co., Inc., Replimune Group, Inc., Oncolytics Biotech Inc., Sorrento Therapeutics, Inc., Transgene SA, PsiOxus Therapeutics Ltd, OncoSec Medical Incorporated, Targovax ASA, SillaJen, Inc.
Key Takeaways
- Oncolytic virus therapies are emerging as a differentiated pillar in oncology, leveraging advances in virology, genetic engineering, and immunomodulation to enhance tumor selectivity and minimize collateral impact.
- Strategic alliances between biopharma companies and research institutes are expediting development timelines, while diversified viral platforms support flexible adaptation to evolving cancer indications.
- Combination strategies with immunotherapies and targeted agents are driving superior clinical responses, addressing the limitations of single-modality approaches, and increasing potential market reach.
- Manufacturing innovations, such as continuous bioprocessing and cell culture optimization, are enhancing scalability and consistency in production to support late-stage clinical and commercial requirements.
- End user dynamics are shifting, with hospitals facilitating initial adoption; research institutes contributing to early-stage innovation; and specialty clinics supporting decentralized, patient-centric models.
Tariff Impact: Navigating US Trade Policy Changes
The introduction of United States tariffs on raw materials and viral vector components in 2025 presents new cost pressures and logistical complexities. Biopharmaceutical firms are actively diversifying supplier networks and localizing manufacturing to mitigate risks and sustain research productivity. These developments are compelling leaders to re-examine supply chain resilience and optimize commercial strategies amid evolving global trade dynamics.
Methodology & Data Sources
This report integrates peer-reviewed studies, clinical trial databases, intellectual property filings, and proprietary industry data. Primary research—including interviews with virologists, oncologists, manufacturing experts, and regulatory specialists—ensures robust, actionable insights. Analytical rigor is maintained through cross-source validation and expert panel reviews, providing confidence in strategic conclusions about the oncolytic virus therapies landscape.
Why This Report Matters
- Enables informed investment and go-to-market decisions by offering a comprehensive landscape review of technology, regulatory, and competitive positioning.
- Highlights transformative trends and actionable intelligence to accelerate therapy development and enhance commercial readiness.
- Supports organizations in identifying partnership opportunities and anticipating shifts in patient, payer, and provider needs globally.
Conclusion
Oncolytic virus therapies are charting a dynamic course in oncology, shaped by advances in science, manufacturing, and partnership models. This report offers senior stakeholders a clear, strategic overview designed to empower market entry, innovation, and growth planning.
Additional Product Information:
- Purchase of this report includes 1 year online access with quarterly updates.
- This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.
Table of Contents
3. Executive Summary
4. Market Overview
7. Cumulative Impact of Artificial Intelligence 2025
Companies Mentioned
The companies profiled in this Oncolytic Virus Therapies market report include:- Amgen Inc.
- Merck & Co., Inc.
- Replimune Group, Inc.
- Oncolytics Biotech Inc.
- Sorrento Therapeutics, Inc.
- Transgene SA
- PsiOxus Therapeutics Ltd
- OncoSec Medical Incorporated
- Targovax ASA
- SillaJen, Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 189 |
| Published | November 2025 |
| Forecast Period | 2025 - 2032 |
| Estimated Market Value ( USD | $ 153.79 Million |
| Forecasted Market Value ( USD | $ 444.83 Million |
| Compound Annual Growth Rate | 16.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
